Drug intelligence / Profile preview

QR-336

Development stage: Discontinued
Lead developer: Quigley Pharma
Modality: Small Molecules
Administration: Oral

Overview

QR-336 is a discontinued antiviral drug candidate that was developed by Quigley Pharma, a subsidiary of The Quigley Corporation. It was primarily investigated for the treatment and prevention of influenza, including highly pathogenic strains such as avian influenza (H5N1). Described as a naturally derived or botanical compound, QR-336 was intended to provide broad-spectrum antiviral activity. The drug reached early-stage clinical development (Phase 1/2) before the program was discontinued following corporate restructuring and the eventual sale of the company's primary assets.

Beyond the preview

Go deeper on QR-336.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on QR-336.

Explore the full profile